Hemogenyx Pharmaceuticals Plc
HEMO.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | £1 | £1 | £3 | £0 |
| Gross Profit | -£1 | -£1 | -£3 | -£0 |
| % Margin | – | – | – | – |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £5 | £5 | £1 | £1 |
| SG&A Expenses | £5 | £5 | £1 | £1 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | -£0 | -£0 | £2 | £1 |
| Operating Expenses | £5 | £5 | £3 | £3 |
| Operating Income | -£6 | -£6 | £4 | -£3 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | £0 | -£1 | £2 | -£2 |
| Pre-Tax Income | -£6 | -£7 | -£4 | -£5 |
| Tax Expense | £0 | £0 | £0 | £2 |
| Net Income | -£6 | -£7 | -£4 | -£5 |
| % Margin | – | – | – | – |
| EPS | -1.7 | -2.37 | -1.62 | -2.64 |
| % Growth | 28.3% | -46.3% | 38.6% | – |
| EPS Diluted | -1.7 | -2.37 | -1.62 | -2.64 |
| Weighted Avg Shares Out | 3 | 3 | 2 | 2 |
| Weighted Avg Shares Out Dil | 3 | 3 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £3 |
| Depreciation & Amortization | £1 | £1 | £1 | £0 |
| EBITDA | -£5 | -£6 | -£3 | -£2 |
| % Margin | – | – | – | – |